Although AEterna Laboratories Inc. missed the primary endpoint in a Phase III trial of Neovastat in renal-cell carcinoma, the company Wednesday said a subgroup of earlier-stage cancer patients demonstrated a significant survival benefit. (BioWorld Today) Read More
